Cadrenal Therapeutics (NASDAQ:CVKD) announced a quiet but material expansion of its clinical platform on December 12, 2025, advancing trial preparation, manufacturing, and clinical leadership.
The company added a Factor XIa program to target acute hospital anticoagulation and acquired VLX-1005, a Phase 2 asset with Orphan Drug and Fast Track designations for heparin-induced thrombocytopenia (HIT).
Management positions Cadrenal with complementary chronic and acute assets—tecarfarin for chronic care, Factor XIa for hospital use, and VLX-1005 for HIT—potentially shifting investor perception if clinical progress becomes visible.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.